---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-006191"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-28T00:02:57.402659+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara receives FDA Complete Response Letter for EBVALLO BLA due to third-party manufacturing issues

## Summary
- FDA CRL solely related to third-party manufacturer inspection findings; no clinical efficacy/safety issues, no new trials requested.
- Atara expects resubmission within 6 months after GMP compliance resolved; potential approval within 6 months of resubmission.
- Preliminary cash and investments ~$43M as of Dec 31, 2024; non-binding term sheet with Redmile for up to $15M equity line.
- Atara exploring strategic alternatives; may suspend CAR-T activities if no funding by Q1 2025; committed to preserving EBVALLO value.
- Atara remains eligible for $60M milestone from Pierre Fabre upon FDA approval and double-digit royalties.

## SEC filing metadata
- accession: 0000950170-25-006191
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/0000950170-25-006191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/atra-20250116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-006191
- JSON: https://secwatch.observer/filing/0000950170-25-006191.json
- Plain text: https://secwatch.observer/filing/0000950170-25-006191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.